Linda Morgan

Linda Morgan

Auto-generated profile, based on publicly available information

Linda Morgan

School of Life Sciences, University of Nottingham, Nottingham, UK

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TCThe FINNPEC Consortium
The FINNPEC Consortium
RMRalph McGinnis
Ralph McGinnis
TCThe GOPEC Consortium
The GOPEC Consortium
VSValgerdur Steinthorsdottir
Valgerdur Steinthorsdottir
NWNicholas O Williams
Nicholas O Williams
LMLinda Morgan
Linda Morgan
Preeclampsia, which affects approximately 5% of pregnancies, is a leading cause of maternal and perinatal death1. The causes of preeclampsia remain unclear, but there is evidence for inherited susceptibility2. Genome-wide association studies (GWAS) have not identified maternal sequence variants of genome-wide significance that replicate in independent data sets3,4. We report the first GWAS of offspring from preeclamptic pregnancies and discovery of the first genome-wide significant susceptibility locus (rs4769613; P = 5.4 × 10−11) in 4,380 cases and 310,238 controls. This locus is near the FLT1 gene encoding Fms-like tyrosine kinase 1, providing biological support, as a placental isoform of this protein (sFlt-1) is implicated in the pathology of preeclampsia5. The association was strongest in offspring from pregnancies in which preeclampsia developed during late gestation and offspring birth weights exceeded the tenth centile. An additional nearby variant, rs12050029, associated with preeclampsia independently of rs4769613. The newly discovered locus may enhance understanding of the pathophysiology of preeclampsia and its subtypes.

25 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
VSValgerdur Steinthorsdottir
Valgerdur Steinthorsdottir
RMRalph McGinnis
Ralph McGinnis
NWNicholas O. Williams
Nicholas O. Williams
LSLilja Stefansdottir
Lilja Stefansdottir
GTGudmar Thorleifsson
Gudmar Thorleifsson
KSKari Stefansson
Kari Stefansson
Preeclampsia is a serious complication of pregnancy, affecting both maternal and fetal health. In genome-wide association meta-analysis of European and Central Asian mothers, we identify sequence variants that associate with preeclampsia in the maternal genome atZNF831/20q13 andFTO/16q12. These are previously established variants for blood pressure (BP) and theFTOvariant has also been associated with body mass index (BMI). Further analysis of BP variants establishes that variants atMECOM/3q26,FGF5/4q21 andSH2B3/12q24 also associate with preeclampsia through the maternal genome. We further show that a polygenic risk score for hypertension associates with preeclampsia. However, comparison with gestational hypertension indicates that additional factors modify the risk of preeclampsia.

15 March 2006 in Clinical Science
Verified
Journal Article
Closed access
SCSally Chappell
Sally Chappell
LMLinda Morgan
Linda Morgan
Pre-eclampsia and its related syndromes are significant causes of maternal and fetal death, but much remains unclear about the underlying disease mechanisms. Epidemiological research has consistently demonstrated a familial predisposition to pre-eclampsia, which has encouraged genetic research in this area. The goal is the discovery of susceptibility genes which will inform understanding of the pathophysiology of pre-eclampsia, and may prove to be targets for therapeutic or preventative strategies. This review examines the application of molecular technologies to the search for genetic clues in pre-eclampsia and emphasizes the importance of integrative approaches. The results of recent genome-wide linkage studies have been particularly encouraging, identifying a number of loci which merit closer examination. Candidate gene studies have proved less fruitful, generating conflicting and inconclusive results. Possible explanations and remedies for this deficiency are discussed with a view to stimulating closer collaboration between researchers in this field.

1 June 1999 in Journal Of Hypertension
Verified
Journal Article
Closed access
LMLinda Morgan
Linda Morgan
FFFiona Foster
Fiona Foster
RHRichard Hayman
Richard Hayman
SCSarah Crawshaw
Sarah Crawshaw
PBPhilip N. Baker
Philip N. Baker
NKNoor Kalsheker
Noor Kalsheker
To investigate the hypothesis that preeclampsia is associated with a common insertion–deletion polymorphism in the angiotensin-converting enzyme gene. Seventy-two women with pre-eclampsia and 83 normotensive pregnant women participated in the study. Pre-eclampsia was defined as a blood pressure exceeding 140/90 mmHg in a previously normotensive woman, associated with proteinuria in excess of 300 mg/l in a 24 h collection. Samples for fetal genotyping were available from 66 pregnancies complicated by pre-eclampsia and 79 normotensive pregnancies. Maternal and fetal samples were genotyped at the insertion–deletion (I–D) polymorphism in intron 16 of the angiotensin-converting enzyme gene by the polymerase chain reaction followed by agarose electrophoresis. Neither the I–D genotype distributions nor the allele frequencies differed significantly between preeclamptic and normotensive pregnancies in maternal or fetal samples (χ2 < 0.3, not significant). The odds ratio for pre-eclampsia in women with the DD genotype, compared with the ID and II genotype, was 1.09 (95% confidence interval 0.55–2.16). The odds ratio associated with the DD genotype in the fetus was 1.14 (0.56–2.32). This study has found no evidence that the insertion–deletion polymorphism in the angiotensinconverting enzyme gene is associated with pre-eclampsia.

27 May 2004 in Human Mutation
Verified
Journal Article
Closed access
PDF file
SPSally Plummer
Sally Plummer
CTClare Tower
Clare Tower
PAPedro Alonso
Pedro Alonso
LMLinda Morgan
Linda Morgan
PBPhil Baker
Phil Baker
NKNoor Kalsheker
Noor Kalsheker
Angiotensin II (AII) acts as a growth factor in local systems, mediating diverse effects such as cellular proliferation and apoptosis. These effects are controlled through two main receptor subtypes: AGTR1 and AGTR2. We studied the haplotype frequencies of both receptor genes in women with preeclamptic pregnancies and normotensive pregnant women. We also looked for any association between AGTR1 genotype at sites in the 5′ flanking region and binding of AII to platelets, which express AGTR1, in 58 normotensive pregnant women. There were nine common haplotypes of AGTR1, with no significant difference in haplotype frequency between the two groups of women. Platelet AII binding in normotensive pregnant women was associated with the genotype at g.5245C>T in the 5′ flanking region of AGTR1 (GenBank AF245699.1), with CC homozygotes at g.5245 having the lowest levels, and g.5245 TT homozygotes having the highest levels (P=0.05). Two novel polymorphisms were identified in AGTR2 (GenBank AY324607.1) at nucleotides g.1701T>C and g.2184A>T. Variation of AGTR2 could be explained by the existence of four common haplotypes. There was evidence for a significant increase in the frequency of the haplotype TAATGC at nucleotides g.1701, g.2041, g.2184, g.4673, g.4679, and g.4975, respectively (P=0.004), in women with preeclampsia. Hum Mutat 24:14–20, 2004.

22 August 2001 in Human Genetics
Verified
Journal Article
Closed access
PDF file
Kevin MorganKevin Morgan
Kevin Morgan
FLFederico Licastro
Federico Licastro
LTLouise Tilley
Louise Tilley
ARAlistair Ritchie
Alistair Ritchie
LMLinda Morgan
Linda Morgan
NKNoor Kalsheker
Noor Kalsheker